Animace načítání

Stránka se připravuje...

Přihlásit se Registrovat se
29 082 právních předpisů

Další údaje zde

Technická podpora

Poskytujeme technickou podporu zdarma

Zavolejte nám

+420 777 717 492

Plné znění - 32022R0692

  1. Úvodní strana
  2. Právní předpisy EU
  3. Plné znění - 32022R0692

Na co čekáte? Nečekejte už ani minutu.
Získejte přístup na tento text ještě dnes. Kontaktujte nás a my Vám obratem uděláme nabídku pro Vás přímo na míru.

Chci získat výhodný přístup

NAŘÍZENÍ KOMISE X&xxxx;XXXXXXXXX XXXXXXXXX (EU) 2022/692

xx xxx 16. února 2022,

kterým xx xxx účely xxxxxxxxxxxx xxxxxxxxxxxxxxxxxx xxxxxxx xxxx xxxxxxxx Xxxxxxxxxx xxxxxxxxxx a Rady (ES) x.&xxxx;1272/2008 x&xxxx;xxxxxxxxxxx, označování x&xxxx;xxxxxx xxxxx x&xxxx;xxxxx

(Xxxx x&xxxx;xxxxxxxx pro EHP)

EVROPSKÁ XXXXXX,

x&xxxx;xxxxxxx xx Smlouvu x&xxxx;xxxxxxxxx Xxxxxxxx xxxx,

x&xxxx;xxxxxxx xx nařízení Xxxxxxxxxx xxxxxxxxxx x&xxxx;Xxxx (XX) x.&xxxx;1272/2008 ze dne 16.&xxxx;xxxxxxxx&xxxx;2008 x&xxxx;xxxxxxxxxxx, označování x&xxxx;xxxxxx xxxxx a směsí, x&xxxx;xxxxx x&xxxx;xxxxxxx xxxxxxx 67/548/XXX a 1999/45/ES x&xxxx;x&xxxx;xxxxx xxxxxxxx (ES) x.&xxxx;1907/2006&xxxx;(1), x&xxxx;xxxxxxx xx čl. 37 xxxx.&xxxx;5 xxxxxxxxx xxxxxxxx,

xxxxxxxx x&xxxx;xxxxx xxxxxxx:

(1)

Xxxxxxx 3 x&xxxx;xxxxx 3 přílohy XX xxxxxxxx (XX) x.&xxxx;1272/2008 xxxxxxxx xxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxx a označení xxxxxxxxxxxx xxxxx xx xxxxxxx kritérií xxxxxxxxxxx x&xxxx;xxxxxxx 2 až 5 xxxxxxx X&xxxx;xxxxxxxxx xxxxxxxx.

(2)

Xxxxxxxx xxxxxxxx pro xxxxxxxx xxxxx (xxxx xxx „xxxxxxxx“) xxxx x&xxxx;xxxxxxx x&xxxx;xxxxxxx&xxxx;37 nařízení (XX) č. 1272/2008 xxxxxxxxxx xxxxxx xx xxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxx x&xxxx;xxxxxxxx xxxxxxxxx látek x&xxxx;xx xxxxxxxxxxx xxxx xxxxxxx xxxxxxxxxxxxxxx klasifikací x&xxxx;xxxxxxxx xxxxxxxxx xxxxxx xxxxx. Xxxx, xx Výbor xxx xxxxxxxxxx rizik (XXX) xxxxxxxx zohlednil xxxxxxxxxx xxxxxxxxxxxx stran, xxxxxx k těmto xxxxxxx xxxxxxxxxxx stanoviska (2):

—

stanovisko ze xxx 5. prosince 2019 xxx xxxxxxxxx, 1,1,1-xxxxxxxxx-X-(xxxxxxxxxxxxxx)-, produkty xxxxxxxxx x&xxxx;xxxxxx křemičitým; xxxxxxxxx xxxxxxxxxx xxxxxxx xxxx křemičitý x&xxxx;xxxxxxxxx x&xxxx;xxxxxxxxxx xxxxxxx,

—

xxxxxxxxxx xx xxx 4.&xxxx;xxxxxx&xxxx;2020 pro xxxxxxxxxx (ISO), [(3-xxxxxx-4-xxxxxxxxxx)xxxxxxxxxx]-3-(2,2-xxxxxxxxxxxx)-2,2-xxxxxxxxxxxxxxxxxxx-1-xxxxxxxxxx,

—

xxxxxxxxxx xx dne 4.&xxxx;xxxxxx&xxxx;2020 xxx β-cyfluthrin (XXX); xxxxxxx xxxx: xxx-(X)-xxxx(4-xxxxx-3-xxxxxxxxxxx)xxxxxx-(1X,3X)-3-(2,2-xxxxxxxxxxxxxx)-2,2-xxxxxxxxxxxxxxxxxxx-1-xxxxxxxxxx x&xxxx;xxx-(X)-xxxx(4-xxxxx-3-xxxxxxxxxxx)xxxxxx- (1X,3X)-3-(2,2-xxxxxxxxxxxxxx)-2,2-xxxxxxxxxxxxxxxxxxx-1-xxxxxxxxxx,

—

xxxxxxxxxx xx xxx 4.&xxxx;xxxxxx&xxxx;2020 xxx xxxxxxxxxxx (XXX); (1X)-X-[(6-xxxxxxxxxxxx-3-xx)xxxxxx]-X’-xxxx-X-xxxxxxxxxxxxxxxxxxx; (X)-X 1-[(6-xxxxx-3-xxxxxxx)xxxxxx]-X 2-kyan-N 1-xxxxxxxxxxxxxxxx,

—

xxxxxxxxxx ze xxx 11.&xxxx;xxxxxx&xxxx;2020 xxx xxxxxx,

—

xxxxxxxxxx xx xxx 11.&xxxx;xxxxxx&xxxx;2020 xxx oxid telluričitý,

—

stanovisko xx dne 11.&xxxx;xxxxxx&xxxx;2020 xxx xxxxxxxxxxxxxx 2,2-xxxxxxxxxxxxxx-1-xxx; 3-xxxx-2,2-xxx(xxxxxxxxxx)xxxxxx-1-xx,

—

xxxxxxxxxx ze xxx 11.&xxxx;xxxxxx&xxxx;2020 pro piperonylbutoxid (XXX); 5-{[2-(2-butoxyethoxy)ethoxy]methyl}-6-propyl-1,3-benzodioxol,

—

stanovisko ze xxx 11.&xxxx;xxxxxx&xxxx;2020 xxx xxxxxxxxxx,

—

xxxxxxxxxx ze dne 11.&xxxx;xxxxxx&xxxx;2020 pro xxx-1,7,7-xxxxxxxxxxxxxxxx[2.2.1]xxxx-2-xx-xxxxxxx; xxxxxxxxx-xxxxxxx,

—

xxxxxxxxxx xx dne 11.&xxxx;xxxxxx&xxxx;2020 pro daminozid (XXX); 4-(2,2-xxxxxxxxxxxxxxxxx)-4-xxxxxxxxxxxx xxxxxxxx; X-(xxxxxxxxxxxxx)xxxxxxxxxxxx xxxxxxxx,

—

xxxxxxxxxx ze xxx 11.&xxxx;xxxxxx&xxxx;2020 xxx xxxxxxxxxxx (XXX); 3,6-xxx(x-xxxxxxxxxx)-1,2,4,5-xxxxxxxx,

—

xxxxxxxxxx xx xxx 11.&xxxx;xxxxxx&xxxx;2020 xxx xxxxxxxxxxx (ISO); 2,6-xxxxxxx-X-[3-xxxxx-5-(xxxxxxxxxxxxxx)-2-xxxxxxx]xxxxxxxxxxxxxx,

—

xxxxxxxxxx xx dne 11.&xxxx;xxxxxx&xxxx;2020 pro xxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 11.&xxxx;xxxxxx&xxxx;2020 xxx 2-ethylhexanovou kyselinu x&xxxx;xxxx xxxx,

—

xxxxxxxxxx xx xxx 11.&xxxx;xxxxxx&xxxx;2020 xxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxxxx xxxxxxxx {[(karboxymethyl)imino]bis(ethylennitrilo)}tetraoctové kyseliny x&xxxx;xxxxxx xxxxxxxxxxxx x&xxxx;xxxxxxxxxxxxxxx xxxx xx žádost Xxxxxxxx komise,

—

stanovisko xx xxx 17.&xxxx;xxxx&xxxx;2020 xxx xxxxxxxxxx-xxx(2-xxxxxxxxxxxxx),

—

xxxxxxxxxx xx xxx 17.&xxxx;xxxx&xxxx;2020 pro xxxxxxxxxx-xxxxxxxx,

—

xxxxxxxxxx xx xxx 17.&xxxx;xxxx&xxxx;2020 xxx xxxxxxxxx barnato-diboritý,

—

stanovisko xx xxx 17.&xxxx;xxxx&xxxx;2020 xxx xxxxxxxxxxx (ISO); 2-xxxxx-3-xxxxx-1,4-xxxxxxxxxxx,

—

xxxxxxxxxx xx dne 17.&xxxx;xxxx&xxxx;2020 xxx 4,4’-xxxxx(xxxxxxxxxxxxxxxxxxxxx),

—

xxxxxxxxxx xx dne 17.&xxxx;xxxx&xxxx;2020 xxx xxxxxx-4-xxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 17.&xxxx;xxxx&xxxx;2020 xxx xxxxxxxxx; 1,3-dimethyl-3,7-dihydro-1H-purin-2,6-dion,

—

stanovisko xx xxx 17.&xxxx;xxxx&xxxx;2020 pro 1,3-xxx(1-xxxxxxxxxx-1-xxxxxxxxxxx)xxxxxx; [x-XXXXX],

—

xxxxxxxxxx xx xxx 17.&xxxx;xxxx&xxxx;2020 xxx 1,3-xxx(xxxxxxxxxxxxxxxx)xxxxxx; [x-XXX],

—

xxxxxxxxxx ze xxx 17.&xxxx;xxxx&xxxx;2020 xxx 2,4,6-xxxxxxxxxxxx-x-xxxxxxx-xxxxxxxxxxx,

—

xxxxxxxxxx xx dne 17.&xxxx;xxxx&xxxx;2020 xxx xxxxxxx xxxxxxxx X-(2-xxxxxxxxxx)xxxxxxxxxx,

—

xxxxxxxxxx xx xxx 17. září 2020 xxx xxxxx,

—

xxxxxxxxxx xx xxx 17.&xxxx;xxxx&xxxx;2020 pro 2-xxxxx-2-{[(1-xxxxxxxx)xxx]xxxxxx}xxxxxx-1,3-xxxx-xxxxxxxxx; 2,2-xxx(xxxxxxxxxxxxxxxxx)xxxxx-xxxxxxx; xxxxxxxxxxxxxxxxx-xxxxxxxxxx,

—

xxxxxxxxxx xx xxx 17.&xxxx;xxxx&xxxx;2020 xxx 1,5-xxxxxxxxxxxxxxxxxxxx [obsahující &xx;&xxxx;0,1&xxxx;% xxxx. částic s aerodynamickým xxxxxxxx menším xxx 50 μx],

—

xxxxxxxxxx ze xxx 17. září 2020 pro 1,5-xxxxxxxxxxxxxxxxxxxx [xxxxxxxxxx ≥ 0,1 % xxxx. xxxxxx s aerodynamickým xxxxxxxx menším než 50 μx],

—

xxxxxxxxxx xx xxx 8. října 2020 xxx xxxxxx xxxxxx,

—

xxxxxxxxxx xx xxx 8.&xxxx;xxxxx&xxxx;2020 xxx 2,4,6-xxx-xxxx-xxxxxxxxxx,

—

xxxxxxxxxx ze dne 8.&xxxx;xxxxx&xxxx;2020 xxx pyridalyl (XXX); 2,6-dichlor-4-(3,3-dichlorallyloxy)fenyl{3-[5-(trifluormethyl)-2-pyridyloxy]propyl}ether,

—

stanovisko ze xxx 8. října 2020 xxx xxxxxxx-2-xxxxx-1-xxxx, sodnou xxx; xxxxxx xxx xxxxxxxxxx; xxxxxxxxx xxxxx,

—

xxxxxxxxxx xx xxx 8. října 2020 xxx X-(5-xxxxx-2-xxxxxxxxxxxxxxx)-X-xxxxxxxxxxx-3-(xxxxxxxxxxxxx)-5-xxxxx-1-xxxxxx-1X-xxxxxxx-4-xxxxxxxxxx; isoflucypram,

—

stanovisko ze xxx 8. října 2020 xxx 2-(2-xxxxxxxxxxxxx)xxxxxxx; xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx,

—

xxxxxxxxxx ze xxx 8.&xxxx;xxxxx&xxxx;2020 pro 4,4′-xxxxxxxxxxxxxxxxxxxx; xxxxxxxx A,

—

stanovisko xx xxx 8.&xxxx;xxxxx&xxxx;2020 xxx xxxxxxxxxxxxx (XXX); X-(1-xxxxxxxxxxx)-2,6-xxxxxxx-3,4-xxxxxxx,

—

xxxxxxxxxx xx xxx 8.&xxxx;xxxxx&xxxx;2020 xxx xxxxxxxxxxxxx (XXX); (2X)-2-{2-[(2,5-xxxxxxxxxxxxxx)xxxxxx]xxxxx}-2-(xxxxxxxxxxxx)-X-xxxxxxxxxxxxxx; (E)-2-(methoxyimino)-N-methyl-2-[α-(2,5-xylyloxy)-o-tolyl]acetamid,

—

stanovisko xx xxx 10. prosince 2020 xxx 4,4’-xxxxxxxxxxxxxxx; xxxxxxxx X,

—

xxxxxxxxxx ze dne 10.&xxxx;xxxxxxxx&xxxx;2020 pro 2-{X-xxxxx-4-[(5-xxxxxxxxxxxx-2-xx)xxx]-x-xxxxxxxxx}xxxxx-xxxxxx; X.X. Disperse Xxxx 124,

—

xxxxxxxxxx ze xxx 10.&xxxx;xxxxxxxx&xxxx;2020 xxx xxxxxxxx xxxxxxxxxxxxxxxxxx; kyselinu xxxxxxxxxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 10.&xxxx;xxxxxxxx&xxxx;2020 xxx methyl-N-(isopropoxykarbonyl)-L-valyl-(3RS)-3-(4-chlorfenyl)-β-alaninát; valifenalát,

—

stanovisko xx dne 10.&xxxx;xxxxxxxx&xxxx;2020 xxx 6-[xxxxx-(X12-X18, xxxxxxxxxx, xxxxxxxxxx)-2,5-xxxxxxxxxxxxxxx-1-xx]xxxxxxxxx xxxxxxxx, sodné x&xxxx;xxxx(2-xxxxxxxxxxxx)xxxxxx xxxx,

—

xxxxxxxxxx ze xxx 10.&xxxx;xxxxxxxx&xxxx;2020 pro 6-[xxxxx-(X10-X13, rozvětvené, nenasycené)-2,5-dioxopyrrolidin-1-yl]hexanovou xxxxxxxx,

—

xxxxxxxxxx ze dne 10.&xxxx;xxxxxxxx&xxxx;2020 xxx 6-[alkyl-(C12-C18, xxxxxxxxxx, nenasycené)-2,5-dioxopyrrolidin-1-yl]hexanovou kyselinu,

—

stanovisko xx dne 10. prosince 2020 xxx 1,3,5-xxxxxxx-2,4,6-xxxxxxx; xxxxxxx,

—

xxxxxxxxxx xx xxx 10.&xxxx;xxxxxxxx&xxxx;2020 xxx xxxxxxx xxxx: 3-(xxxxxxxxxxxxx)-1-xxxxxx-X-[(1XX,4XX,9XX)-1,2,3,4-xxxxxxxxxx-9-xxxxxxxxx-1,4-xxxxxxxxxxxxxxx-5-xx]xxxxxxx-4-xxxxxxxxxx x&xxxx;3-(xxxxxxxxxxxxx)-1-xxxxxx-X-[(1XX,4XX,9XX)-1,2,3,4-xxxxxxxxxx-9-xxxxxxxxx-1,4-xxxxxxxxxxxxxxx-5-xx]xxxxxxx-4-xxxxxxxxxx [xxxxxxxxx xxxxx ≥&xxxx;78&xxxx;% xxx-xxxxxxx x&xxxx;≤&xxxx;15&xxxx;% xxxx-xxxxxxx], isopyrazam,

—

stanovisko xx xxx 10. prosince 2020 xxxxxxx xxxxxxx, extraktu [x&xxxx;xxxxx xxxxxxxx Azadirachta xxxxxx, xxxxxxxxxxx vodou x&xxxx;xxxx zpracovaný xxxxxxxxxxx xxxxxxxxxxxx],

—

xxxxxxxxxx ze xxx 10.&xxxx;xxxxxxxx&xxxx;2020 pro oxid xxxxxxxxx,

—

xxxxxxxxxx xx xxx 10.&xxxx;xxxxxxxx&xxxx;2020 xxx xxxxxxxx (XXX), 3-isopropyl-2,1,3-benzothiadiazin-4-on-2,2-dioxid,

—

stanovisko xx xxx 10.&xxxx;xxxxxxxx&xxxx;2020 xxxxxxx xxxxxxxxxx posouzení nových xxxxxxxxx x&xxxx;xxxxxx xxxxxxxxx xxxxxxxx 2-xxxxxxxxxxx-1-xxx; xxxxxxxxxxxxx-xxxxxxxxx-xxxxxx (XXXX) xx xxxxxx Xxxxxxxx xxxxxx.

(3)

Xxxx obdrženy xxxxxxxxx informace, které xxxxxxxxxxx vědecké posouzení xxxxxxx xx stanoviscích XXX xx dne 11.&xxxx;xxxxxx&xxxx;2020 xxx 2-xxxxxxxxxxxxxx xxxxxxxx x&xxxx;xxxx xxxx; xx xxx 11.&xxxx;xxxxxx&xxxx;2020 xxxxxxx opětovného xxxxxxxxx xxxxxxxx toxicity {[(karboxymethyl)imino]bis(ethylennitrilo)}tetraoctové xxxxxxxx a jejích pentasodných x&xxxx;xxxxxxxxxxxxxxx xxxx na xxxxxx Evropské xxxxxx, xx xxx 8.&xxxx;xxxxx&xxxx;2020 xxx xxxxxx xxxxxx, xx xxx 10. prosince 2020 xxx xxxx vanadičný, xx dne 10.&xxxx;xxxxxxxx&xxxx;2020 xxxxxxx opětovného posouzení xxxxxx xxxxxxxxx o akutní xxxxxxxxx toxicitě 2-xxxxxxxxxxx-1-xxx; xxxxxxxxxxxxx-xxxxxxxxx-xxxxxx (XXXX) xx xxxxxx Xxxxxxxx komise x&xxxx;xx xxx 10.&xxxx;xxxxxxxx&xxxx;2020 xxx melamin.

(4)

Komise tyto xxxxxxxxx xxxxxxxxx xxxxxxxxx x&xxxx;xxxxxxxxxx xx xx xxxxxxxxxx x&xxxx;xxxx, aby xxxxxxxxxxx xxxxxxxx analýzu xxxxxxxxx xx xxxxxxxxxxxx XXX. Na xxxxxxx xxxxxxxxx provedeného x&xxxx;xxxxxxxxx xxxxxxxxxxxx xx proto xxxxxx xxxxxx, aktualizovat xxxx zrušit harmonizovanou xxxxxxxxxxx x&xxxx;xxxxxxxx xxxxxxxxx xxxxx.

(5)

Xxxx, xx xxxx Xxxxxx předáno stanovisko XXX, xxxx obdrženy xxxxxxxxx xxxxxxxxx xxxxxxxx xx akutní xxxxxxxxx xxxxxxxx silanaminu, 1,1,1-trimethyl-N-(trimethylsilyl)-, xxxxxxxx hydrolýzy x&xxxx;xxxxxx xxxxxxxxxx; xxxxxxxxxxx xxxxxxxxxxxx xxxxxxxxx oxidu xxxxxxxxxxx x&xxxx;xxxxxxxxx x&xxxx;xxxxxxxxxx xxxxxxx. Xxxxxxxxxxx silanaminu, 1,1,1-xxxxxxxxx-X-(xxxxxxxxxxxxxx)-, xxxxxxxx xxxxxxxxx s oxidem xxxxxxxxxx; xxxxxxxxxxx xxxxxxxxxxxx xxxxxxxxx oxidu křemičitého x&xxxx;xxxxxxxxx x&xxxx;xxxxxxxxxx xxxxxxx xxxx xxxxxx xxxxxxxxx xxxxxxxx kategorie 2, xxxxxxxxxx ve xxxxxxxxxx XXX ze xxx 5.&xxxx;xxxxxxxx&xxxx;2019, by xxxxxx xxx xxxxxxxx xx xxxxxxx XX xxxxxxxx (XX) x.&xxxx;1272/2008, neboť Xxxxxx xxxx xxxxxxx xxxxxxxxx xxxxxxxxx x&xxxx;xxxxxxxxxx, xx xx bylo xxxxx xxxxx xxxxxxxxx XXX. Xx xxxxxxx XX xxxxxxxx (XX) x.&xxxx;1272/2008 by xxxx xxxx xxx zařazena xxxxxxxxxxx této xxxxx xxxx XXXX RE 2, doporučená xx xxxxxxxxxx výboru XXX xx xxx 5.&xxxx;xxxxxxxx&xxxx;2019, xxxxx xxxxxx xxxxxxxx xxxxx xxxx xxxxxxxxx, xxxxx xx vyžadovaly xxxxx posouzení xxxx xxxxxxxxxxx.

(6)

Xxxxxxxx (XX) x.&xxxx;1272/2008 xx xxxxx xxxx xxx xxxxxxxxxxxxx způsobem xxxxxxx.

(7)

Xxxxxxxxxx nových nebo xxxxxxxxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxx xx nemělo být xxxxxxxxxx ihned, xxxxxxx xxxxxxxxxx potřebují xxxxxxx xxxx xx to, xxx xxxxxxxxxxxx označování x&xxxx;xxxxxx látek a směsí xxxxx nebo xxxxxxxxxxxxxx xxxxxxxxxxxx x&xxxx;xxxxxxx xxxxxxxxx xxxxxx, xx xxxxx xx vztahují xxxxxxxxx xxxxxxxxxxx xxxxxxxxx. Xxxx xxxx je xxxxxx xxxxxxxx k tomu, xxx xxxxxxxxxx měli xxxxxxxx xxxx přijmout opatření xxxxx x&xxxx;xxxxxxxxx trvalého xxxxxxxxxx xxxxxxx xxxxxxxx xxxxxxxxx, xxxxx xxxxxxxx x&xxxx;xxxxxxxx xxxx xxxxxxxxxxx xxxxx tohoto xxxxxxxx. Xxxxxxxxxxx xx xxxx xxxx být xxxxxxxx xxxxxxxx xxxx xxxx xxxxxxxxxxxxx harmonizované xxxxxxxxxxx x&xxxx;xxxxxxxxxxxxx způsobem xxxxxxxxxxx xxxxxxxxxx a balení xx xxxxxxxxxxx xxxxxxx před xxxxx xxxxxxxxxxxxx tohoto xxxxxxxx, xxx xxxx xxxxxxxxx xxxxxx xxxxxx xxxxxxx xxxxxxxx zdraví x&xxxx;xxxxxxxxx xxxxxxxxx a aby xx xxxxxxxxxxx xxxxxxxx xxxxxxxxxx pružnost,

PŘIJALA XXXX XXXXXXXX:

Xxxxxx&xxxx;1

Xxxxx xxxxxxxx (XX) x.&xxxx;1272/2008

Xxxxxxx VI nařízení (XX) x.&xxxx;1272/2008 se xxxx x&xxxx;xxxxxxx s přílohou xxxxxx xxxxxxxx.

Xxxxxx&xxxx;2

Xxxxx x&xxxx;xxxxxxxx x&xxxx;xxxxxxxxxxxx

Xxxx xxxxxxxx xxxxxxxx x&xxxx;xxxxxxxx xxxxxxxx xxxx xx xxxxxxxxx x&xxxx;Xxxxxxx věstníku Xxxxxxxx xxxx.

Xxxxxxx se xxx dne 23.&xxxx;xxxxxxxxx 2023.

Xxxxxxxx xx druhého xxxxxxxxxxx xxxxxx xxxxxx xxxxx xxx xxxxx x&xxxx;xxxxx klasifikovány, xxxxxxxxxx x&xxxx;xxxxxx x&xxxx;xxxxxxx x&xxxx;xxxxx xxxxxxxxx xxx dne xxxx vstupu v platnost.

Xxxx xxxxxxxx xx xxxxxxx x&xxxx;xxxxx xxxxxxx x&xxxx;xxxxx xxxxxxxxxx xx xxxxx xxxxxxxxx státech.

V Bruselu xxx 16. února 2022.

Xx Xxxxxx

xxxxxxxxxxx

Xxxxxx XXX XXX XXXXX

(1)&xxxx;&xxxx;Xx. xxxx. X&xxxx;353, 31.12.2008, s. 1.

(2)  Stanoviska jsou xxxxxxxx xx této xxxxxxxxxxx xxxxxxx: xxxxx://xxxx.xxxxxx.xx/xxxxxxxx-xx-xxx-xxxxxxxxxx-xxxxx-xxxxxxx/-/xxxxxxx/xxxx/-/xxXxxxxx/-/xxxXxxxxx/-/xxx_xxxxxxxXxxx/-/xxx_xxxxxxxXx/-/xxx_xxxxxx_xxxxxx/Xxxxxxx+Xxxxxxx/xxx_xxxxxxxxxXxxx/-/xxx_xxxxxxxxxXx/-/xxx_xxxxxxxx_xxxxxxxxxxXxxx/-/xxx_xxxxxxxx_xxxxxxxxxxXx/-/xxx_xxxxxxxx_xxxxxxxxXxxx/-/xxx_xxxxxxxx_xxxxxxxxXx/-/xxx_xxxxxxxx_xxxxxx/-/xxx_xxxxxxxxx/-/xxx_xxxxxxxxxxXxxx/-/xxx_xxxxxxxxxxXx/-/xxx_xxxxxxxxxx_xxxxxxxxx/-/. – Xxxxxxxxxx ze xxx 11. června 2020 a ze xxx 10. prosince 2020 xxxxxxxx xx xxxxxxxxxx posouzení xx xxxxxx Xxxxxxxx xxxxxx xxxx x&xxxx;xxxxxxxxx xx této internetové xxxxxxx: https://echa.europa.eu/about-us/who-we-are/committee-for-risk-assessment/opinions-of-the-rac-adopted-under-specific-echa-s-executive-director-requests

PŘÍLOHA

Příloha XX xxxxxxxx (XX) x.&xxxx;1272/2008 xx xxxx takto:

1)

v části 3 xx xxxxxxx 3 xxxx xxxxx:

x)

xxxxxxxx xx xxxx položky:

Indexové xxxxx

Xxxxxxxx xxxxx

Xxxxx XX

Xxxxx CAS

Klasifikace

Označení

Specifické xxxxxxx. xxxxxx, xxxxxxxxxxxxx xxxxxxx x&xxxx;XXX

Xxxxxxxx

Xxxx tříd x&xxxx;xxxxxxxxx xxxxxxxxxxxxx

Xxxx xxxxxxxxxxxx xxx o nebezpečnosti

Kódy xxxxxxxxxxx xxxxxxx x&xxxx;xxxxxxxxxx xxxx

Xxxx xxxxxxxxxxxx xxx x&xxxx;xxxxxxxxxxxxx

Xxxx xxxxx. xxxxxxxxxxxx vět x&xxxx;xxxxxxxxxxxxx

„014-052-00-7

xxxxxxxxx, 1,1,1-xxxxxxxxx-X-(xxxxxxxxxxxxxx)-, xxxxxxxx xxxxxxxxx s oxidem xxxxxxxxxx; xxxxxxxxx xxxxxxxxxx amorfní xxxx xxxxxxxxx x&xxxx;xxxxxxxxx x&xxxx;xxxxxxxxxx xxxxxxx

272-697-1

68909-20-6

XXXX RE 2

X373 (plíce) (xxxxxxxxxx)

XXX08

Xxx

X373 (xxxxx) (xxxxxxxxxx)

XXX066“

„035-005-00-7

xxxxxx xxxxxx

235-183-8

12124-97-9

Xxxx. 1X

Xxxx.

XXXX SE 3

XXXX XX 1

Xxx Xxxxx. 2

X360XX

X362

X336

X372 (xxxxxxx systém)

H319

GHS08

GHS07

Dgr

H360FD

H362

H336

H372 (xxxxxxx systém)

H319“

„050-032-00-4

dibutylcín-bis(2-ethylhexanoát)

220-481-2

2781-10-4

Muta. 2

Xxxx. 1X

XXXX XX 1

X341

X360XX

X372 (xxxxxxxx xxxxxx)

XXX08

Xxx

X341

X360XX

X372 (imunitní xxxxxx)“

„050-033-00-X

xxxxxxxxxx-xxxxxxxx

213-928-8

1067-33-0

Xxxx. 2

Xxxx. 1X

XXXX XX 1

H341

H360FD

H372 (xxxxxxxx xxxxxx)

XXX08

Xxx

X341

X360XX

X372 (imunitní xxxxxx)“

„052-001-00-0

xxxxxx

236-813-4

13494-80-9

Xxxx. 1X

Xxxx.

X360Xx

X362

XXX08

Xxx

X360Xx

X362“

„052-002-00-6

xxxx xxxxxxxxxxx

231-193-1

7446-07-3

Xxxx. 1X

Xxxx.

X360Xx

X362

XXX08

Xxx

X360Xx

X362“

„056-005-00-3

xxxxxxxxx xxxxxxx-xxxxxxxx

237-222-4

13701-59-2

Xxxx. 1X

Xxxxx Xxx. 4

Xxxxx Xxx. 3

X360XX

X332

X301

XXX08

XXX06

Xxx

X360XX

X332

X301

xxxxxxxxx:

XXX&xxxx;= 1,5&xxxx;xx/x (prach nebo xxxx)

xxxxxx:

XXX&xxxx;= 100 mg/kg TH“

„601-097-00-8

propylbenzen

203-132-9

103-65-1

Flam. Xxx. 3

Asp. Tox. 1

XXXX XX 3

Xxxxxxx Xxxxxxx 2

X226

X304

X335

X411

XXX02

XXX08

XXX07

XXX09

Xxx

X226

X304

X335

X411“

„603-243-00-6

xxxxxxxxxxxxxx 2,2-xxxxxxxxxxxxxx-1-xxx; 3-xxxx-2,2-xxx(xxxxxxxxxx)xxxxxx-1-xx

253-057-0

36483-57-5; 1522-92-5

Xxxx. 1X

Xxxx. 2

X350

X341

XXX08

Xxx

X350

X341“

„604-096-00-0

xxxxxxxxxxxxxxxx (XXX); 5-{[2-(2-xxxxxxxxxxxx)xxxxxx]xxxxxx}-6-xxxxxx-1,3-xxxxxxxxxxx

200-076-7

51-03-6

XXXX XX 3

Xxx Xxxxx. 2

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X335

X319

X400

X410

XXX07

XXX09

Xxx

X335

X319

X410

XXX066

X&xxxx;= 1

X&xxxx;= 1“

„604-097-00-6

2,4,6-xxx-xxxx-xxxxxxxxxx

211-989-5

732-26-3

Xxxx. 1B

Acute Tox. 4

XXXX XX 2

Xxxx Xxxx. 1X

X360X

X302

X373 (xxxxx)

X317

XXX08

XXX07

Xxx

X360X

X302

X373 (xxxxx)

X317

xxxxxx:

XXX&xxxx;= 500&xxxx;xx/xx TH“

„604-098-00-1

4,4’-sulfonyldifenol; xxxxxxxx X

201-250-5

80-09-1

Xxxx. 1X

X360XX

XXX08

Xxx

X360XX“

„606-153-00-5

xxxxxxxxxx

204-337-6

119-61-9

Xxxx. 1X

X350

XXX08

Xxx

X350“

„606-154-00-0

xxxxxxxxxxx (ISO); 2-amino-3-chlor-1,4-naftochinon

220-529-2

2797-51-5

Carc. 2

Xxxx. 2

Xxxxx Tox. 4

XXXX XX 2

Xxx Xxxxx. 2

Xxxx Sens. 1&xxxx;X

Xxxxxxx Xxxxx 1

Aquatic Xxxxxxx 1

X351

X361x

X302

X373 (krevní xxxx, xxxxxxx)

X319

X317

X400

X410

XXX08

XXX07

XXX09

Xxx

X351

X361x

X302

X373 (xxxxxx xxxx, xxxxxxx)

X319

X317

X410

xxxxxx:

XXX&xxxx;= 500&xxxx;xx/xx XX

X&xxxx;= 10

X&xxxx;= 10“

„607-756-00-6

xxx-1,7,7-xxxxxxxxxxxxxxxx[2.2.1]xxxx-2-xx-xxxxxxx; xxxxxxxxx-xxxxxxx

227-561-6

5888-33-5

Xxxx Xxxx. 1 A

H317

GHS07

Wng

H317“

„607-757-00-1

daminozid (XXX); 4-(2,2-xxxxxxxxxxxxxxxxx)-4-xxxxxxxxxxx xxxxxxxx; X-(xxxxxxxxxxxxx)xxxxxxxxxxx xxxxxxxx

216-485-9

1596-84-5

Xxxx. 2

X351

XXX08

Xxx

X351“

„607-758-00-7

4,4′-xxxxx(xxxxxxxxxxxxxxxxxxxxx)

201-286-1

80-51-3

Xxxx-xxxxx. X

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X242

X400

X410

XXX02

XXX09

Xxx

X242

X410

X&xxxx;= 1

X&xxxx;= 1“

„607-759-00-2

xxxxxx-4-xxxxxxxxxxxxxxx

216-407-3

1576-35-8

Xxxx-xxxxx. X

X242

XXX02

Xxx

X242“

„607-760-00-8

2-{X-xxxxx-4-[(5-xxxxxxxxxxxx-2-xx)xxx]-x-xxxxxxxxx}xxxxx-xxxxxx; C.I. Xxxxxxxx Xxxx 124

239-203-6

15141-18-1

Skin Xxxx. 1&xxxx;X

X317

XXX07

Xxx

X317

Xxxx Xxxx. 1&xxxx;X; X317: C ≥ 0,001 %“

„607-761-00-3

perfluorheptanová xxxxxxxx; xxxxxxxxxxxxxxxxxxxxx xxxxxxxx

206-798-9

375-85-9

Xxxx. 1X

XXXX XX 1

H360D

H372 (xxxxx)

XXX08

Xxx

X360X

X372 (xxxxx)“

„607-762-00-9

xxxxxx-X-(xxxxxxxxxxxxxxxxxx)-X-xxxxx-(3XX)-3-(4-xxxxxxxxxx)-β-xxxxxxxx; xxxxxxxxxxx

-

283159-90-0

Xxxx. 2

Xxxxxxx Xxxxxxx 2

X351

X411

XXX08

XXX09

Xxx

X351

X411“

„607-763-00-4

6-[xxxxx-(X12-X18, xxxxxxxxxx, nenasycené)-2,5-dioxopyrrolidin-1-yl]hexanová kyselina, xxxxx x&xxxx;xxxx(2-xxxxxxxxxxxx)xxxxxx xxxx

-

-

Xxxx. 1X

Xxx Xxxxx. 2

H360FD

H319

GHS08

GHS07

Dgr

H360FD

H319“

„607-764-00-X

6-[alkyl-(C10-C13, xxxxxxxxxx, nenasycené)-2,5-dioxopyrrolidin-1-yl]hexanová xxxxxxxx

-

2156592-54-8

Xxxx. 1X

Xxx Xxxxx. 2

H360FD

H319

GHS08

GHS07

Dgr

H360FD

H319“

„607-765-00-5

6-[alkyl-(C12-C18, xxxxxxxxxx, xxxxxxxxxx)-2,5-xxxxxxxxxxxxxxx-1-xx]xxxxxxxx kyselina

-

-

Repr. 1X

X360XX

XXX08

Xxx

X360XX“

„613-341-00-0

xxxxxxxxxxx (XXX); 3,6-xxx(x-xxxxxxxxxx)-1,2,4,5-xxxxxxxx

277-728-2

74115-24-5

Xxxxxxx Xxxxxxx 1

H410

GHS09

Wng

H410

M = 1“

„613-342-00-6

xxxxxxxxx; 1,3-xxxxxxxx-3,7-xxxxxxx-1X-xxxxx-2,6-xxxx

200-385-7

58-55-9

Xxxx. 1X

X360X

XXX08

Xxx

X360X“

„613-343-00-1

xxxxxxxxx (ISO); 2,6-xxxxxxx-4-(3,3-xxxxxxxxxxxxxxx)xxxxx{3-[5-(xxxxxxxxxxxxxx)-2-xxxxxxxxxx]xxxxxx}xxxxx

-

179101-81-6

Xxxx Xxxx. 1

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X317

X400

X410

XXX07

XXX09

Xxx

X317

X410

X&xxxx;= 1&xxxx;000

X&xxxx;= 100“

„613-344-00-7

pyridin-2-thiol-1-oxid, xxxxx xxx; sodná xxx xxxxxxxxxx; pyrithion xxxxx

223-296-5;

240-062-8

3811-73-2;

15922-78-8

Xxxxx Xxx. 3

Xxxxx Xxx. 3

Xxxxx Xxx. 4

XXXX XX 1

Xxxx Xxxxx. 2

Eye Xxxxx. 2

Xxxx Xxxx. 1

Aquatic Xxxxx 1

Xxxxxxx Chronic 2

X331

X311

X302

X372 (xxxxxxx xxxxxx)

X315

X319

X317

X400

X411

XXX06

XXX08

XXX09

Xxx

X331

X311

X302

X372 (xxxxxxx xxxxxx)

X315

X319

X317

X410

XXX070

xxxxxxxxx:

XXX&xxxx;= 0,5&xxxx;xx/x (xxxxx xxxx mlha)

dermální:

ATE = 790&xxxx;xx/xx TH

orální:

ATE = 500&xxxx;xx/xx XX

X&xxxx;= 100“

„613-345-00-2

1,3,5-xxxxxxx-2,4,6-xxxxxxx;

xxxxxxx

203-615-4

108-78-1

Xxxx. 2

XXXX XX 2

X351

X373 (xxxxxx xxxxx)

XXX08

Xxx

X351

X373 (močové cesty)“

„615-046-00-2

1,3-bis(1-isokyanato-1-methylethyl)benzen; [x-XXXXX]

220-474-4

2778-42-9

Xxxx. Sens. 1

Skin Xxxx. 1&xxxx;X

X334

X317

XXX08

Xxx

X334

X317“

„615-047-00-8

1,3-xxx(xxxxxxxxxxxxxxxx)xxxxxx; [x-XXX]

222-852-4

3634-83-1

Xxxx. Xxxx. 1

Xxxx Xxxx. 1&xxxx;X

X334

X317

XXX08

Xxx

X334

X317

Xxxx Sens. 1&xxxx;X; X317: C ≥ 0,001 %“

„615-048-00-3

2,4,6-triisopropyl-m-fenylen-diisokyanát

218-485-4

2162-73-4

Resp. Sens. 1

Xxxx Xxxx. 1

X334

X317

XXX08

Xxx

X334

X317“

„615-049-00-9

1,5-xxxxxxxxxxxxxxxxxxxx

[xxxxxxxxxx &xx;&xxxx;0,1&xxxx;% hmot. xxxxxx x&xxxx;xxxxxxxxxxxxxx xxxxxxxx xxxxxx xxx 50 μx]

221-641-4

3173-72-6

XXXX XX 3

Skin Xxxxx. 2

Xxx Irrit. 2

Xxxx. Xxxx. 1

Xxxx Sens. 1&xxxx;X

Xxxxxxx Xxxxxxx 3

H335

H315

H319

H334

H317

H412

GHS07

GHS08

Dgr

H335

H315

H319

H334

H317

H412“

„615-050-00-4

1,5-diisokyanatonaftalen

[obsahující &xx;&xxxx;0,1&xxxx;% xxxx. xxxxxx x&xxxx;xxxxxxxxxxxxxx xxxxxxxx xxxxxx xxx 50 μm]

221-641-4

3173-72-6

Acute Xxx. 2

STOT XX 3

Xxxx Xxxxx. 2

Eye Xxxxx. 2

Resp. Xxxx. 1

Xxxx Xxxx. 1&xxxx;X

Xxxxxxx Xxxxxxx 3

X330

X335

X315

X319

X334

X317

X412

XXX06

XXX08

Xxx

X330

X335

X315

X319

X334

X317

X412

xxxxxxxxx:

XXX&xxxx;= 0,27&xxxx;xx/x (xxxxx xxxx xxxx)“

„616-237-00-3

xxxxxxxxxxx (XXX); 2,6-dichlor-N-[3-chlor-5-(trifluormethyl)-2-pyridyl]methylbenzamid

-

239110-15-7

Repr. 2

H361d

GHS08

Wng

H361d“

„616-238-00-9

triamid xxxxxxxx X-(2-xxxxxxxxxx)xxxxxxxxxx

477-690-9

874819-71-3

Xxxx. 1X

XXXX XX 2

X360Xx

X373 (xxxxxxx)

XXX08

Xxx

X360Xx

X373 (xxxxxxx)“

„616-239-00-4

X-(5-xxxxx-2-xxxxxxxxxxxxxxx)-X-xxxxxxxxxxx-3-(xxxxxxxxxxxxx)-5-xxxxx-1-xxxxxx-1X-xxxxxxx-4-xxxxxxxxxx; xxxxxxxxxxxx

-

1255734-28-1

Xxxx. 2

Acute Xxx. 4

Skin Xxxx. 1X

Xxxxxxx Acute 1

Aquatic Xxxxxxx 1

X361x

X332

X317

X400

X410

XXX08

XXX07

XXX09

Xxx

X361x

X332

X317

X410

xxxxxxxxx:

XXX&xxxx;= 2,2&xxxx;xx/x (xxxxx xxxx xxxx)

X&xxxx;= 10

X&xxxx;= 1“

„616-240-00-X

reakční xxxx: 3-(xxxxxxxxxxxxx)-1-xxxxxx-X-[(1XX,4XX,9XX)-1,2,3,4-xxxxxxxxxx-9-xxxxxxxxx-1,4-xxxxxxxxxxxxxxx-5-xx]xxxxxxx-4-xxxxxxxxxx x&xxxx;3-(xxxxxxxxxxxxx)-1-xxxxxx-X-[(1XX,4XX,9XX)-1,2,3,4-xxxxxxxxxx-9-xxxxxxxxx-1,4-xxxxxxxxxxxxxxx-5-xx]xxxxxxx-4-xxxxxxxxxx [relativní xxxxx ≥&xxxx;78&xxxx;% syn-isomerů x&xxxx;≤&xxxx;15&xxxx;% xxxx-xxxxxxx], xxxxxxxxxx

-

881685-58-1

Xxxx. 2

Xxxx. 1B

Skin Xxxx. 1X

Xxxxxxx Xxxxx 1 Xxxxxxx Chronic 1

X351

X360X

X317

X400

X410

XXX08

XXX07

XXX09

Xxx

X351

X360X

X317

X410

Xxxx. 1X; X360X:

X&xxxx;≥&xxxx;3&xxxx;%

X&xxxx;= 10

X&xxxx;= 10“

„650-058-00-1

Xxxxxxx, extrakt [z jader xxxxxxxx Xxxxxxxxxxx xxxxxx, xxxxxxxxxxx vodou a dále xxxxxxxxxx xxxxxxxxxxx rozpouštědly]

283-644-7

84696-25-3

Repr. 2

Xxxx Xxxx. 1

Xxxxxxx Xxxxxxx 1

X361x

X317

X410

XXX08

XXX07

XXX09

Xxx

X361x

X317

X410

X&xxxx;= 10“

x)

xxxxxxx xxxxxxxxxxxx indexovým xxxxxx 014-001-00-9; 023-001-00-8; 601-024-00-X; 603-014-00-0; 603-107-00-6; 604-030-00-0; 607-111-00-9; 607-230-00-6; 607-253-00-1; 607-254-00-7; 607-734-00-6; 607-735-00-1; 607-736-00-7; 608-032-00-2; 609-042-00-X; 613-012-00-1; 616-164-00-7 xx xxxxxxxxx xxxxxx xxxxxxxxx:

Xxxxxxxx xxxxx

Xxxxxxxx xxxxx

Xxxxx ES

Číslo XXX

Xxxxxxxxxxx

Xxxxxxxx

Xxxxxxxxxx xxxxxxx. xxxxxx, xxxxxxxxxxxxx xxxxxxx x&xxxx;XXX

Xxxxxxxx

Xxxx xxxx x&xxxx;xxxxxxxxx xxxxxxxxxxxxx

Xxxx xxxxxxxxxxxx vět o nebezpečnosti

Kódy xxxxxxxxxxx symbolů x&xxxx;xxxxxxxxxx xxxx

Xxxx xxxxxxxxxxxx vět x&xxxx;xxxxxxxxxxxxx

Xxxx xxxxx. xxxxxxxxxxxx xxx o nebezpečnosti

„014-001-00-9

trichlorsilan

233-042-5

10025-78-2

Flam. Xxx. 1

Xxxxx-xxxxx. 1

Acute Xxx. 3

Xxxxx Tox. 4

Xxxx Xxxx. 1&xxxx;X

Xxx Xxx. 1

X224

X260

X331

X302

X314

X318

XXX02

XXX06

XXX05

Xxx

X224

X260

X331

X302

X314

XXX014

XXX029

XXX071

xxxxxxxxx:

XXX&xxxx;= 7,6 mg/l (páry)

orální:

ATE = 1&xxxx;000 &xxxx;xx/xx XX“

„023-001-00-8

xxxx xxxxxxxxx

215-239-8

1314-62-1

Xxxx. 2

Xxxx. 1X

Xxxx. 2

Xxxx.

Xxxxx Xxx. 3

Xxxxx Xxx. 2

XXXX XX 3

XXXX RE 1

Xxxxxxx Xxxxxxx 2

H341

H350

H361fd

H362

H301

H330

H335

H372 (dýchací xxxxx, xxxxxxxxxx)

X411

XXX06

XXX08

XXX09

Xxx

X341

X350

X361xx

X362

X301

X330

X335

X372 (dýchací xxxxx, xxxxxxxxxx)

X411

xxxxxxxxx:

XXX&xxxx;= 0,05&xxxx;xx/x (xxxxx xxxx xxxx)

xxxxxx:

XXX&xxxx;= 220&xxxx;xx/xx TH“

„601-024-00-X

kumen

202-704-5

98-82-8

Flam. Xxx. 3

Xxxx. 1X

Xxx. Xxx. 1

XXXX SE 3

Aquatic Xxxxxxx 2

X226

X350

X304

X335

X411

XXX02

XXX08

XXX07

XXX09

Xxx

X226

X350

X304

X335

X411“

„603-014-00-0

2-xxxxxxxxxxx-1-xx; xxxxxxxxxxxxx-xxxxxxxxx-xxxxx

203-905-0

111-76-2

Xxxxx Xxx. 3

Xxxxx Xxx. 4

Xxxx Irrit. 2

Xxx Xxxxx. 2

X331

X302

X315

X319

XXX06

Xxx

X331

X302

X315

X319

xxxxxxxxx:

XXX&xxxx;= 3 mg/l (xxxx)

xxxxxx:

XXX&xxxx;= 1&xxxx;200  mg/kg XX“

„603-107-00-6

2-(2-xxxxxxxxxxxxx)xxxxxxx; xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx

203-906-6

111-77-3

Xxxx. 1X

X360X

XXX08

Xxx

X360X

Xxxx. 1X; H360D: C ≥ 3 %“

„604-030-00-0

4,4′-isopropylidendifenol; xxxxxxxx A

201-245-8

80-05-7

Repr. 1B

STOT XX 3

Eye Xxx. 1

Xxxx Xxxx. 1

Xxxxxxx Xxxxx 1

Aquatic Chronic 1

X360X

X335

X318

X317

X400

X410

XXX08

XXX07

XXX05

XXX09

Xxx

X360X

X335

X318

X317

X410

X&xxxx;= 1

X&xxxx;= 10“

„607-111-00-9

2-xxxxx-2-{[(1-xxxxxxxx)xxx]xxxxxx}xxxxxx-1,3-xxxx-xxxxxxxxx; 2,2-xxx(xxxxxxxxxxxxxxxxx)xxxxx-xxxxxxx;

xxxxxxxxxxxxxxxxx-xxxxxxxxxx

239-701-3

15625-89-5

Xxxx. 2

Xxxx Irrit. 2

Xxx Xxxxx. 2

Xxxx Xxxx. 1

Aquatic Xxxxx 1

Xxxxxxx Xxxxxxx 1

H351

H315

H319

H317

H400

H410

GHS08

GHS07

GHS09

Wng

H351

H315

H319

H317

H410

M = 1

X&xxxx;= 1

X“

„607-230-00-6

2-xxxxxxxxxxxxx xxxxxxxx x&xxxx;xxxx xxxx, x&xxxx;xxxxxxxx xxxx, xxxxx xxxx xxxxxxx jinde x&xxxx;xxxx xxxxxxx

-

-

Xxxx. 1X

X360X

XXX08

Xxx

X360X“

„607-253-00-1

xxxxxxxxxx (XXX); [(3-xxxxxx-4-xxxxxxxxxx)xxxxxxxxxx]-3-(2,2-xxxxxxxxxxxx)-2,2-xxxxxxxxxxxxxxxxxxx-1-xxxxxxxxxx

269-855-7

68359-37-5

Xxxx.

Xxxxx Tox. 2

Xxxxx Xxx. 2

STOT SE 1

Xxxxxxx Xxxxx 1

Aquatic Xxxxxxx 1

X362

X330

X300

X370 (nervový xxxxxx)

X400

X410

XXX06

XXX08

XXX09

Xxx

X362

X330

X300

X370 (xxxxxxx xxxxxx)

X410

xxxxxxxxx:

XXX&xxxx;= 0,14&xxxx;xx/x (xxxxx xxxx xxxx)

xxxxxx:

XXX&xxxx;= 14&xxxx;xx/xx XX

X&xxxx;= 1&xxxx;000&xxxx;000

X&xxxx;= 1&xxxx;000&xxxx;000 “

„607-254-00-7

β-xxxxxxxxxx (XXX); xxxxxxx xxxx: xxx-(X)-xxxx(4-xxxxx-3-xxxxxxxxxxx)xxxxxx-(1X,3X)-3-(2,2-xxxxxxxxxxxxxx)-2,2-xxxxxxxxxxxxxxxxxxx-1-xxxxxxxxxx a rel-(R)-kyan(4-fluor-3-fenoxyfenyl)methyl-(1S,3R)-3-(2,2-dichlorethenyl)-2,2-dimethylcyklopropan-1-karboxylát

-

1820573-27-0

Lact.

Acute Xxx. 2

Xxxxx Tox. 2

STOT XX 1

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X362

X330

X300

X370 (xxxxxxx xxxxxx)

X400

X410

XXX06

XXX08

XXX09

Xxx

X362

X330

X300

X370 (nervový xxxxxx)

X410

xxxxxxxxx:

XXX&xxxx;= 0,081&xxxx;xx/x (xxxxx xxxx xxxx)

xxxxxx:

XXX&xxxx;= 11&xxxx;xx/xx XX

X&xxxx;= 1 000 000

M = 1 000 000 “

„607-734-00-6

xxxxxxxxxxx-2,2‘,2“,2“‘,2“&xxxx;“ -(xxxxx-1,2-xxxxxxxxxxx)xxxxxxxxxxx

404-290-3

7216-95-7

Xxxx. 1X

Xxxxx Xxx. 4

XXXX XX 2

Xxx Xxxxx. 2

X360X

X332

X373 (xxxxxxxxxx)

X319

XXX08

XXX07

Xxx

X360X

X332

X373 (vdechování)

H319

Repr. 1B; X360X: C ≥ 3 %

inhalační:

ATE = 1,5&xxxx;xx/x (xxxxx nebo xxxx)“

„607-735-00-1

{[(xxxxxxxxxxxxx)xxxxx]xxx(xxxxxxxxxxxxxx)}xxxxxxxxxxx xxxxxxxx

200-652-8

67-43-6

Xxxx. 1X

Xxxxx Xxx. 4

XXXX XX 2

Eye Xxxxx. 2

X360X

X332

X373 (xxxxxxxxxx)

X319

XXX08

XXX07

Xxx

X360X

X332

X373 (xxxxxxxxxx)

X319

Xxxx. 1X; X360X: X&xxxx;≥&xxxx;3&xxxx;%

xxxxxxxxx:

XXX&xxxx;= 1,5&xxxx;xx/x (xxxxx xxxx xxxx)“

„607-736-00-7

xxxxxxxxxxxx-[(xxxxxxxxxxxxxxxxx)xxxxxxxx(xxxxxxxxxxxxxx)xxxxxxxxxxx]

205-391-3

140-01-2

Xxxx. 1B

Acute Xxx. 4

XXXX XX 2

X360X

X332

X373 (xxxxxxxxxx)

XXX08

XXX07

Xxx

X360X

X332

X373 (xxxxxxxxxx)

Xxxx. 1X; H360D: X&xxxx;≥&xxxx;3&xxxx;%

xxxxxxxxx:

XXX&xxxx;= 1,5&xxxx;xx/x (xxxxx xxxx xxxx)“

„608-032-00-2

xxxxxxxxxxx (XXX); (1X)-X-[(6-xxxxxxxxxxxx-3-xx)xxxxxx]-X’-xxxx-X-xxxxxxxxxxxxxxxxxxx; (X)-X 1-[(6-chlor-3-pyridyl)methyl]-N 2-kyan-N 1-xxxxxxxxxxxxxxxx

-

135410-20-7&xxxx;160430-64-8

Xxxx. 2

Xxxxx Xxx. 3

Xxxxxxx Xxxxxxx 1

Xxxxxxx Xxxxx 1

X361x

X301

X410

X400

XXX08

XXX06

XXX09

Xxx

X361x

X301

X410

xxxxxx:

XXX&xxxx;= 140 mg/kg XX

X&xxxx;= 10

M = 10“

„609-042-00-X

xxxxxxxxxxxxx (XXX); X-(1-xxxxxxxxxxx)-2,6-xxxxxxx-3,4-xxxxxxx

254-938-2

40487-42-1

Xxxx. 2

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X361x

X400

X410

XXX08

XXX09

Xxx

X361x

X410

X&xxxx;= 100

X&xxxx;= 10“

„613-012-00-1

xxxxxxxx (XXX); 3-isopropyl-1H-2,1,3-benzothiadiazin-4(3H)-on-2,2-dioxid

246-585-8

25057-89-0

Repr. 2

Acute Xxx. 4

Eye Irrit. 2

Xxxx Xxxx. 1

H361d

H302

H319

H317

GHS08

GHS07

Wng

H361d

H302

H319

H317

orální: XXX&xxxx;= 1&xxxx;600 &xxxx;xx/xx XX“

„616-164-00-7

xxxxxxxxxxxxx (ISO); (2X)-2-{2-[(2,5-xxxxxxxxxxxxxx)xxxxxx]xxxxx}-2-(xxxxxxxxxxxx)-X-xxxxxxxxxxxxxx; (X)-2-(xxxxxxxxxxxx)-X-xxxxxx-2-[α-(2,5-xxxxxxxx)-x-xxxxx]xxxxxxxx

149961-52-4

Xxxx. 2

Repr. 2

Xxxxx Xxx. 4

Aquatic Xxxxx 1

Xxxxxxx Chronic 1

X351

X361x

X332

X400

X410

XXX08

XXX07

XXX09

Xxx

X351

X361x

X332

X410

xxxxxxxxx:

XXX&xxxx;= 1,3&xxxx;xx/x (xxxxx nebo xxxx)

X&xxxx;= 100

M = 100“

x)

xxxxxxx xxxxxxxxxxxx indexovému xxxxx 615-007-00-X se xxxxxxx.